Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3454738 vs placebo in moderate-to-severe atopic dermatitis (China)
CTR20232562Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ucenprubart in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Aug 2023; status: terminated.
02
Drugs
ucenprubart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232562.